• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Canada
  • United Kingdom
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Life Sciences > Biotech needs cash in hesitant market

Biotech needs cash in hesitant market

Apr. 3, 2019 by Matt Wolf

  • email
  • Twitter
  • Facebook
  • Linkedin

Life science companies require a cash infusion at least twice as big as that of 2018 to fund research and development at a time when investors remain skittish, according to a Bloomberg analysis.

The analysis suggests that over 100 biotech companies, including makers of oncology therapies and treatments for other life-threatening conditions, need to raise $7 billion to $8 billion this year, if not significantly more, to sustain research and other operations. That’s up sharply from 2018, when 102 companies raised about $3.6 billion.

Despite a healthy supply of capital, however, investor attitudes toward biotech appear to be hesitant, scared off in part by a surge in volatility in the public markets in the fourth quarter amid global economic concerns. The VIX, an index that measures volatility in equities, peaked on Christmas Eve, and was up again in February and late March.

biotech stock volatility chart

Even so, the balance of global biotech and pharmaceutical venture capital dry powder is approximately $10 billion in closed funds dedicated to biotech, with another $8.4 billion raised, Bloomberg data show. The balance of global dry powder sitting in buyout funds stands at approximately $55 billion, with $3.3 billion raised.

Compared to the broad equity market and the pharmaceutical sector, biotech investment activity is particularly sensitive to volatility shocks like the one U.S. markets experienced in the fourth quarter. The Nasdaq Biotechnology Index fell more than 20 percent in that period.

If recent volatility shocks are any indication, we will not see broad biotech stock performance—considered a proxy of investor interest—recover until late spring or summer. With many investors on the sidelines, biotech startups will need to closely monitor their cash and clearly communicate their value proposition to attract capital.

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • Cyberthreats for middle market companies are increasing--RSM MMBI Survey

    Unauthorized users will attempt to access proprietary data at more than half of the middle market businesses polled by the proprietary RSM US Middle Market Business Index survey in the first quarter—up significantly from 47 percent in 2018—illustrating…

  • Joe Brusuelas and Simon Hart
    Brexit and the middle market: What comes next?

    RSM Chief Economist Joe Brusuelas gives an update on the outlook for middle market companies following the UK's planned departure from the European Union.

  • Cyberthreats for middle market companies are increasing--RSM MMBI Survey

    Unauthorized users will attempt to access proprietary data at more than half of the middle market businesses polled by the proprietary RSM US Middle Market Business Index survey in the first quarter—up significantly from 47 percent in 2018—illustrating…

Filed Under: Life Sciences Tagged With: biotech, life sciences, Matt Wolf, private equity, venture capital

About Matt Wolf

@MattWolfHC

Matt leads RSM’s health care valuation consulting group. In this capacity, Matt helps health care clients evaluate mergers, acquisitions, joint ventures, and other growth strategies.

In January 2018, Matt was selected as a senior analyst RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions impacting middle market leaders. Matt’s focus is the health care and life sciences space.

Primary Sidebar

Other Regions

  • Canada
  • United Kingdom

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Life Science articles

5 things to know in life sciences: Week of March 1

Mar. 4, 2021

5 things to know in life sciences: Week of Feb. 22

Feb. 26, 2021

5 things to know in life sciences: Week of Feb. 15

Feb. 19, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences